How does nivolumab's immune function lead to skin issues?

Nivolumab is a PD-1–inhibiting cancer immunotherapy. By blocking PD-1, it removes a normal brake on T cells, boosting their activity against tumors. That same heightened T-cell activity can also cause autoimmune-like inflammation in healthy tissues, including the skin. Here’s how that leads to skin issues:

- Core idea: PD-1 blockade amplifies T‑cell responses and can break peripheral tolerance. Autoreactive T cells may attack skin cells or skin antigens, leading to inflammation and rashes.

- What changes in the skin:
- Increased skin inflammation with T cells and cytokines (like IFN-γ, TNF-α, IL-2) can cause various eruptions.
- Skin-resident memory T cells can become reactivated, sustaining dermatitis.

- Common skin problems you might see:
- Rash and pruritus (itchy skin) – the most frequent.
- Vitiligo (loss of skin color in patches) is relatively common in melanoma patients treated with PD‑1 inhibitors, reflecting autoimmune destruction of melanocytes.
- Dermatitis types such as lichenoid or eczematous patterns.
- Psoriasis-like rashes or flares in some people.

- Less common but more serious issues:
- Bullous pemphigoid or other bullous diseases.
- Erythema multiforme, Stevens-Johnson syndrome (rare but serious).

- Timing:
- Can occur days to months after starting nivolumab; new symptoms can appear at any time during treatment.

- How it’s managed (high level):
- Mild cases: topical steroids and antihistamines may help; may continue nivolumab with close monitoring.
- Moderate to severe cases: may require holding nivolumab and/or systemic steroids or other immune-suppressing treatment, possibly with dermatology input.
- Severe or life-threatening skin reactions require urgent medical evaluation.

If you or someone on nivolumab develops a new skin rash, itching, or changes in skin color, it’s important to contact a clinician promptly, especially if there are widespread rashes, blistering, fever, or mucous membrane involvement. This is a general explanation—specific advice should come from a treating physician.